Calcemin Advance tablets, No. 30

Prevention and complex treatment of osteoporosis of various origins:

- in women during menopause (natural and surgical);

- in persons taking corticosteroids and immunosuppressants for a long time;

therapy of diseases of the musculoskeletal system: to improve the consolidation of traumatic fractures;

Replenishment of calcium and micronutrient deficiencies in adolescents.

Inside, during meals.

Complex therapy of osteoporosis: 1 tab. 2 times a day.

Prevention of osteoporosis: 1 tab. in a day.

When using the drug for the prevention and in the complex therapy of osteoporosis, the duration of treatment is determined by the doctor individually. The average duration of the course for prevention is 2 months; in the treatment of osteoporosis - 3 months.

Therapy of diseases of the musculoskeletal system: to improve the consolidation of traumatic fractures - 1 table. in a day; the duration of treatment is 4Ц6 weeks.

Replenishment of calcium and trace element deficiency in adolescents from 12 years old: 1 table. in a day. The average duration of treatment is 4Ц6 weeks.

Pink film-coated tablets, oval, biconvex, with a line on one side.

1 tab.

calcium (in the form of calcium citrate tetrahydrate and calcium carbonate) 500 mg

colecalciferol (vit. D3) 200 IU

magnesium (in the form of magnesium oxide) 40 mg

zinc (in the form of zinc oxide) 7.5 mg

copper (in the form of copper oxide) 1 mg

manganese (in the form of manganese sulfate) 1.8 mg

boron (in the form of sodium borate decahydrate) 250 mcg

Excipients: maltodextrin - 25 mg, microcrystalline cellulose - 49.05 mg, croscarmellose sodium - 38 mg, stearic acid - 16.3 mg, soy polysaccharide - 15 mg, sodium lauryl sulfate - 5 mg.

• Increased individual sensitivity to the components of the drug;

• allergic reaction to peanut butter and soybeans; the preparation contains soy polysaccharide;

• vitamin D hypervitaminosis;

• hypercalcemia and hypercalciuria;

• severe renal failure;

• urolithiasis disease;

• nephrolithiasis;

• active form of tuberculosis;

• sarcoidosis;

• children's age (up to 12 years old).

With care: during pregnancy and lactation; renal failure.

pharmachologic effect

Combined preparation containing vitamins, micro- and macroelements; the action is due to the properties that make up the ingredients.

Calcium is involved in the formation of bone tissue, reduces resorption and increases bone density, prevents diseases of the musculoskeletal system, helps to strengthen bone tissue and joints. Calcium citrate ensures the absorption of calcium, regardless of the functional state of the gastrointestinal tract, which is applicable for the treatment of patients with reduced secretory function of the gastrointestinal tract, as well as during treatment with drugs to reduce secretion; reduces the level of markers of bone resorption, which indicates a slowdown in the processes of destruction of bone tissue; regulates the content of parathyroid hormone, which leads to improved regulation of calcium homeostasis; does not increase the content of oxalates and calcium in the urine, therefore does not cause the formation of kidney stones; does not block the absorption of iron, which reduces the risk of developing iron deficiency anemia.

Colecalciferol (vitamin D3) regulates the exchange of calcium and phosphorus in the body, participates in the formation of the bone skeleton, helps preserve the structure of bones, enhances calcium absorption in the intestine and reabsorption of phosphorus in the renal tubules.

Magnesium is involved in the formation of muscle and bone tissue, and also takes part in protein synthesis (including type I collagen).

Zinc promotes the synthesis of sex hormones, which prevents the destruction of bone tissue. It has a beneficial effect on bone density.

Zinc and magnesium are essential for the synthesis of organic bone matrix.

Manganese is involved in the formation of proteoglycans, which improves the quality of bone tissue and forms the protein (collagen) matrix of bone tissue.

Copper is involved in the synthesis of collagen and elastin, which is part of bone and connective tissue, which affects the formation of bone mass.

Boron reduces the excessive activity of parathyroid hormone, improves calcium absorption, reduces the risk of developing cholecalciferol deficiency, and helps prevent osteoporosis.

Side effect

From the digestive system: nausea, vomiting, flatulence, diarrhea, constipation.

From the side of metabolism: hypercalcemia and hypercalciuria.

Allergic reactions: itching, rash, urticaria.

Application during pregnancy and lactation

During pregnancy and breastfeeding, the use of the drug must be agreed with your doctor.

The daily dose for pregnant women should not exceed 1500 mg of calcium and 600 IU of vitamin D3, because hypercalcemia that develops against the background of an overdose during pregnancy can cause defects in the mental and physical development of the child.

In lactating women, it should be borne in mind that cholecalciferol and its metabolites are excreted in breast milk. This should be taken into account when adding calcium and vitamin D3 to a child.

Application for impaired renal function

The use of the drug is contraindicated in severe renal failure and urolithiasis.

The drug should be prescribed with caution in case of renal failure.

Application in children

The use of the drug is contraindicated in children under 12 years of age.

special instructions

The recommended dose should not be exceeded. increased calcium intake can inhibit intestinal absorption of iron, zinc and other essential minerals.

Influence on the ability to drive vehicles and mechanisms

There is no data on the effect of the drug on the speed of psychomotor reactions when driving a car and working with mechanisms.

Overdose

An overdose of the drug can lead to vitamin D3 hypervitaminosis, hypercalcemia and hypercalciuria.

Symptoms: thirst, polyuria, decreased appetite, constipation, nausea, vomiting, dizziness, muscle weakness, headache, fainting, coma, fatigue, bone pain, mental disorders, nephrocalcinosis, abdominal pain, urolithiasis, in severe cases - cardiac arrhythmias. With prolonged use of calcium in doses over 2500 mg - kidney damage, calcification of soft tissues.

Treatment: in case of detection of the first signs of an overdose, the patient must reduce the dose or stop using the drug, consult a doctor. In case of accidental overdose, induce vomiting, rinse the stomach. If necessary, symptomatic therapy is performed.

In the case of hypercalciuria exceeding 7.5 mmol / day (300 mg / day), it is necessary to reduce the dose or stop taking the drug. Recommended rehydration, the use of 'loop' diuretics (for example, furosemide), corticosteroids, calcitonin, bisphosphonates, in severe cases - hemodialysis.

Drug interactions

With the simultaneous use of the drug CalceminЃ Advance with vitamin A, the toxicity of vitamin D3 decreases.

Phenytoin, barbiturates, glucocorticoids reduce the effectiveness of vitamin D3.

Laxatives reduce the absorption of vitamin D3.

Glucocorticoids, hormonal contraceptives for systemic use, levothyroxine reduce the absorption of calcium ions.

With the simultaneous use of the drug with antibiotics of the tetracycline group, the interval between doses should be at least 3 hours, with bisphosphonates and sodium fluoride (their absorption is impaired) - at least 2 hours.

With the simultaneous use of the drug CalceminЃ Advance with cardiac glycosides, the toxicity of the latter increases (monitoring of the ECG and clinical condition is necessary).

With the simultaneous use of the drug with thiazide diuretics, the risk of developing hypercalcemia increases, with furosemide and other 'loop' diuretics - the excretion of calcium by the kidneys increases.

CalceminЃ Advance should not be used in conjunction with calcium channel blockers.

It is not recommended to take the drug simultaneously with antacids that contain aluminum, due to a decrease in their effectiveness.